To the content
2 . 2020

Physiological effects, mechanisms of action and application of lactulose

Abstract

The discovery of lactulose as a bifidogenic factor became the background for the appearance of the prebiotics concept. Currently, lactulose is the most studied in terms of medical use oligosaccharide with a high prebiotic index. The exact mechanisms of action of lactulose remain largely unknown despite a number of new researches based on modern methods of molecular biology, genetics, and bioinformatics.

The aim of this review to summarize and analyze the actual information about biological activity, probable mechanisms of action, and possible uses of lactulose in human nutrition.

Results. The structure of lactulose, methods for its determination and preparation are briefly described. Promising methods for producing lactulose include enzymatic synthesis from lactose using β-galactosidase or epimerase. Information on the physiological effects of lactulose and the mechanisms of its action on the human organism is presented. The works confirming the ability of lactulose to stimulate the growth of bifidobacteria and to influence the metabolism of the intestinal microbiota are summarized. The results of studies of the ability of lactulose to have antitoxic and anticarcinogenic effects are presented. The mechanisms of the positive effect of the prebiotic on the absorption of minerals, increased absorption of Ca and Mg in the human organism are described. The effect of lactulose on immunity and the possibility of its use to reduce the glucose blood level in patients with type 2 diabetes mellitus are shown. The main directions of the use of lactulose in food production are systematized. The data confirming the possibility of using lactulose as a growth factor for probiotics, as well as a protective agent to increase the survival of some starter cultures, are presented. Brief information on the doses and forms of lactulose apply in medicine is presented. The dependence of the effects of lactulose on the dose, health condition and age of patients has been established.

Conclusion. Perspective directions of lactulose using in combination with probiotics, other prebiotics, and as an encapsulating ingredient for vitamins and other functional nutrition ingredients are determined. In this regard, the study of lactulose interaction with the components of complex products is relevant.

Keywords:lactulose, prebiotic, physiological effects, mechanisms of action, application

Funding. The research was supported by the Ministry of Education and Science of the Russian Federation (agreement MON 03.G25.31.0241).

Conflict of interests. The authors declare no conflict of interests.

For citation: Ryabtsevа S.A., Khramtsov A.G., Budkevich R.O., Anisimov G.S., Chuklo A.O., Shpak M.A. Physiological effects, mechanisms of action and application of lactulose. Voprosy pitaniia [Problems of Nutrition]. 2020; 89 (2): 5-20. DOI: 10.24411/0042-8833-2020-10012 (in Russian)

References

1. Gibson G.R., Hutkins R., Sanders M.E., Prescott S.L., Reimer R.A., Salminen S.J., et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017; 14: 491–502.

2. Khramcov A.G., Ryabtseva S. A., Budkevich R.O., et al. Prebiotics as functional food ingredients: terminology, selection criteria and comparative assessment, classification. Voprosy pitaniia [Problems of Nutrition]. 2018; 87 (1): 5–17. (in Russian)

3. Petuely F. Der Bifidusfactor. Dtsch Med Wochenschr. 1957; 82: 1957–60.

4. Mayerhofer F., Petuely F. Untersuchungen zur Regulation der darmträgheit des erwachsenen mit hilfe der lactulose (bifidus-faktor). Wien Klin Wochenschr. 1959; 71: 865–9.

5. Bircher J., Muller J., Guggenheim P., Haemmerli U.P. Treatment of chronic portal-systemic encephalopathy with lactulose. Lancet. 1966; 1: 890–2.

6. Lactulose. A drug with promising future. In: Symposium – Abstracts «Lactulose – 30 years after». Witten, Germany, 1996.

7. Tamura Y., Mizota T., Schimamura S. Lactulose and its application to the food and pharmaceutical industries. Bull Int Dairy Fed. 1994; 289: 43–53.

8. Playne M.J., Crittenden R.G. Galacto-oligosaccharides and others products derived from lactose. Adv Dairy Chem. 2009; 3: 121–201.

9. Schumann C. Medical, nutritional and technological properties of lactulose. Eur J Nutr. 2002; 41: 17–25.

10. Konn G.O., Libertal M.M. Syndromes of hepatic coma and lactulose. Moscow: Meditsina, 1983: 516 р. (in Russian)

11. Terada A., Hara H., Kataoka M., Mitsuoka T. Effect of lactulose on the composition and metabolic activity of the human faecal flora. Microb Ecol Health Dis. 1992; 5: 43–50.

12. Khramtsov A.G., Ryabtseva S.A., Evdokimov I.A., et al. On the use of lactulose in children’s dietary and therapeutic nutrition products. Voprosy pitaniia [Problems of Nutrition]. 1997; (2): 25–6. (in Russian)

13. Sinelnikov B.M., Khramtsov A.G., Evdokimov I.A., et al. Lactose and its derivatives. Saint Petersburg: Professiya, 2007: 786 р. (in Russian)

14. Murzin I.I. The Russian prebiotics market: food ingredients business [Electronic resource]. 2011. URL: http://bfi-online.ru/index.html?kk=014e7d714f&msg=2226 (date of access October 09, 2019) (in Russian)

15. Lactulose [Electronic resource]. URL: https://www.ncbi.nlm.nih.gov/pubmed/?term=lactulose (date of access November 8, 2019)

16. The register of medicines of Russia. Lactulose [Electronic resource]. URL: https://www.rlsnet.ru/mnn_index_id_1041.htm (date of access October 16, 2019) (in Russian)

17. Lactulose [Electronic resource] URL: https://pubchem.ncbi.nlm.nih.gov/compound/11333. (date of access September 10, 2019)

18. Wu J., Jiang P., Chen W., et al. Design and application of a lactulose biosensor. Sci Rep. 2017; 7: 459–94.

19. Ait-Aissa A., Aider M. Lactulose: production and use in functional food, medical and pharmaceutical applications. Practical and critical review. Int J Food Sci Technol. 2014; 49: 1245–53.

20. Silvério S.C., Macedo E.A., Teixeira J.A., et al. Biocatalytic approaches using lactulose: end product compared with substrate. Сompr Rev. 2016; 15: 878–96.

21. Roberfroid M., Gibson G. R., Hoyles L., et al. Prebiotic effects: metabolic and health benefits. Br J Nutr. 2010; 104: 1–63.

22. Rastall R.A., Gibson G.R. Recent developments in prebiotics to selectively impact beneficial microbes and promote intestinal health. Curr Opin Biotechnol. 2015; 32: 42–6.

23. Sakai Y., Seki N., Hamano K., et al. Prebiotic effect of two grams of lactulose in healthy Japanese women: a randomised, double-blind, placebo-controlled crossover trial. Benef Microbes. 2019; 27: 1–12.

24. Sakai Y., Seki N., Hamano H., Ochi H., et al. A study of the prebiotic effect of lactulose at low dosages in healthy Japanese women. Biosci Microbiota Food Health. 2019; 38 (2): 69–72.

25. Rycroft C.E., Jones M.R., Gibson G.R., et al. A comparative in vitro evaluation of the fermentation properties of prebiotic oligosaccharides. J Appl Microbiol. 2001; 91: 878–87.

26. Palframan R., Gibson G.R., Rastall R.A. Development of a quantitative tool for the comparison of the prebiotic effect of dietary oligosaccharides. Lett Appl Microbiol. 2003; 37: 281–4.

27. Ballongue J., Schumann С., Quignon Р. Effects of lactulose and lactitol on colonic microflora and enzymatic activity. Scand J Gastroenterol. 1997; 32: 41–4.

28. Ruszkowski J., Witkowski J.M. Lactulose: patient- and dose-dependent prebiotic properties in humans. Anaerobe. 2019; 59: 100–6.

29. Mao B., Li D., Zhao J., et al. In vitro fermentation of lactulose by human gut bacteria. J Agric Food Chem. 2014; 62: 10 970–7.

30. Bothe M.K., Maathuis A.J.H., Bellmann S., et al. Dose-dependent prebiotic effect of lactulose in a computer-controlled in vitro model of the human large intestine. Nutrients. 2017; 9: 767–76.

31. Hoffmann K. Behandlung von gesunden Salmonellen-Ausscheiden mit Lactulose. Dtsch Med Wochenschr. 1975; 100: 1429–31.

32. Agarwalla A., Weber A., Davey S., et al. Lactulose is associated with decreased risk of Clostridium difficile infection in decompensated cirrhosis. Clin Gastroenterol Hepatol. 2017; 15: 953–4.

33. Shoaf-Sweeney K.D., Hutkins R.W. Adherence, anti-adherence and oligosaccharides preventing pathogens from sticking to the host. Adv Food Nutr Res. 2009; 55: 101–61.

34. Nath A., Haktanirlar G., Varga Á., et al. Biological activities of lactose-derived prebiotics and symbiotic with probiotics on gastrointestinal system. Medicina (Kaunas). 2018; 54 (2): 18.

35. Hafer A., Krämer S., Duncker S., et al. Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study. BMC Gastroenterol. 2007; 7: 36.

36. Chen H.B., Su X.Y. Efficacy and safety of lactulose for the treatment of irritable bowel syndrome. Medicine (Baltimore). 2019; 98 (39): 17 295–8.

37. Luo M., Li L., Lu C.Z., Cao W.K. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol. 2011; 23 (12): 1250–7.

38. Aires F.T., Ramos P.T., Bernardo W.M. Efficacy of lactulose in the prophylaxis of hepatic encephalopathy in cirrhotic patients presenting gastrointestinal bleeding. Rev Assoc Méd Bras. 1992; 62 (3): 243–7.

39. Wang J.Y., Bajaj J.S., Wang J.B., et al. Lactulose improves cognition, quality of life and gut microbiota in minimal hepatic encephalopathy: a multi-center randomized controlled trial. J Dig Dis. 2019; 20: 547–56.

40. Liehr H., Englisch G., Rasenack U. Lactulose – a drug with antiendotoxin effect. Hepatogastroenterology. 1980; 27 (5): 356–60.

41. Liehr H., Heine W.D. Treatment of endotoxemia in galactosamine hepatitis by lactulose administered intravenously. Hepatogastroenterology. 1981; 28 (6): 296–8.

42. Kishor C., Ross R.L., Blanchard H. Lactulose as a novel template for anticancer drug development targeting galectins. Chem Biol Drug Des. 2018; 92 (4): 1801–8.

43. Van Berge Henegouwen G.P., Van der Werf S.D.J., Ruben A.Th. Effect of lactulose on biliary lipid composition. J Hepatol. 1986; 3: 328–32.

44. Nagengast F.M., Hectors M.P.C., Buys W.A.M, Tongeren J.H.M.V. Inhibition of secondary bile acid formation in the large intestine by lactulose in healthy subjects of two different age groups. Eur J Clin Invest. 1988; 18: 56–61.

45. Vogt J.A., Ishii-Schrade K.B., Pencharz P.B., et al. L-rhamnose and lactulose decrease serum triacylglycerols and their rates of synthesis, but do not affect serum cholesterol concentrations in men. J Nutr. 2006; 136: 2160–6.

46. Suzuki K., Endo Y., Uehara M., et al. Effect of lactose, lactulose and sorbitol on mineral utilization and intestinal flora. J Jpn Soc Nutr Food Sci. 1985; 38: 39–42.

47. Igarashi C., Iiyama Y., Kato R., Tomita M., et al. Effect of Bifidobacterium longum and lactulose on the strength of bone in ovariectomized osteoporosis model rats. Bifidus. 1994; 7: 139–47.

48. van den Heuvel E.G.H.M., Weidauer T. Role of the non-digestible carbohydrate lactulose in the absorption of calcium. Med Sci Monit. 1999; 5 (6): 1231–7.

49. Seki N., Hamano H., Iiyama Y., Asano Y., et al. Effect of lactulose on calcium and magnesium absorption: a study using stable isotopes in adult men. J Nutr Sci Vitaminol. 2007; 53: 5–12.

50. Nath A., Molnár M.A., Csighy A., Koszegi K., et al. Biological activities of lactose-based prebiotics and symbiosis with probiotics on controlling osteoporosis, blood-lipid and glucose levels. Medicina (Kaunas). 2018; 54 (6): 98–100.

51. Rowland I.R., Bearn C.A., Fischer R., Pool-Zobel B.L. The effect of lactulose on DNA damage induced by 1,2-dimethylhydrazine in the colon of human-flora-associated rats. Nutr Cancer. 1996; 26: 37–47.

52. Vendemiale G., Palasciano G., Cirelli F., еt al. Crystalline lactulose in the therapy of hepatic cirrhosis: evaluation of clinical and immunological parameters: preliminary results. Drug Res. 1992; 42 (II): 969–72.

53. Fulton J.D. Infection limitation with lactulose therapy. J Clin Exp Gerontol. 1988; 10 (3): 117–24.

54. Budkevich R.O., Evdokimov I.A. The effect of in vitro food lactulose on the membrane and the activity of NA/K-AT causes red blood cells. Izvestiya vysshikh uchebnykh zavedeniy. Pischevaya tehnologiya [News of Higher Educational Institutions. Food Technology]. 2012; (2-3): 39–41. (in Russian)

55. Budkevich R.O., Evdokimov I.A., Emel’yanov S.A., еt al. The biological activity of in vitro food lactulose concentrates according to erythrocyte morphometry by atomic force microscopy. Vestnik Severo-Kavkazskogo federal’nogo universiteta [Bulletin of the North Caucasus Federal University]. 2011; (4): 115–8. (in Russian)

56. Genovese S., Riccardi G., Rivellese A.A. Lactulose improves blood glucose response to an oral glucose test in non-insulin dependent diabetic patients. Diabetes Nutr Metab.1992; 5: 295–7.

57. Bianchi G., Ronchi M., Marchesini G. Effect of lactulose on carbohydrate metabolism and diabetes mellitus. Scand J Gastroenterol Suppl. 1997; 222: 62–4.

58. Steudle J., Schon C., Wargenau M., Pauly L., et al. Blood glucose response after oral intake of lactulose in healthy volunteers: a randomized, controlled, cross-over study. World J Gastrointest Pharmacol Ther. 2018; 9: 22–30.

59. Battle M., Martin T., Fulton J. Lactulose may help prevent urinary tract infections. Br Med J. 2001; 323: 930–7.

60. Baumjohann H., Schumann C., Rentz B. Rezidivierende vaginal- and darmmycosen – mit lactulose zu behandeln. Notabene Med. 1991; 6: 273–5.

61. Collins S.L., McMillan A., Seney S., et al. Promising prebiotic candidate established by evaluation of lactitol, lactulose, raffinose, and oligofructose for maintenance of a Lactobacillus-dominated vaginal microbiota. Appl Environ Microbiol. 2018; 84 (5): 2200–17.

62. Illanes A., Guerrero C., Vera C., et al. Lactose-Derived Prebiotics. Academic Press, 2016: 312 p.

63. Comission Regulation (EU) No 432/2012 of 16 May 2012 establishing a list of permitted health claims made on foods, other than those referring to the reduction of disease risk and to children’s development and health. Official Journal of the European Union [Electronic resource]. URL: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:136:0001:0040:EN:PDF (date of access February 12, 2020)

64. Ryabtseva S.A. Lactulose in fermented milk products: new developments. Pererabotka moloka [Processing of Milk]. 2012; (10): 56–8. (in Russian)

65. Nooshkam M., Babazadeh A., Jooyandeh H. Lactulose: properties, techno-functional food applications, and food grade delivery system. Trends Food Sci Technol. 2018; 80: 23–4.

66. Products enriched with lactulose [Electronic resource] URL: http://www.felizata.ru/produce.php/ (date of access October 10, 19) (in Russian)

67. Özer D., Serdar A., Barbaros O. Effect of inulin and lactulose on survival of Lactobacillus acidophilus La-5 and Bifidobacterium bifidum Bb-02 in acidophilus-bifidus yoghurt. Food Sci. Technol. Int. 2005; 11: 19–24.

68. De Souza Oliveira R.P., Rodrigues Florence A.C., Perego P., et al. Use of lactulose as prebiotic and its influence on the growth, acidification profile and viable counts of different probiotics in fermented skim milk. Int J Food Microbiol. 2011; 145 (1): 22–7.

69. Awad R.A., Hagrass A.E., Salama W.M., et al. Lactulose production from milk permeate and its performance in healthy functional frozen yoghurt. World J Dairy Food Sci. 2014; 9 (1): 1–9.

70. Tabatabaie F., Mortazavi A. Influence of Lactulose on the survival of probiotic strains in yoghurt. World Appl Sci J. 2008; 3 (1): 88–90.

71. Adebola O.O., Corcoran O., Morgan W.A. Synbiotics: the impact of potential prebiotics inulin, lactulose and lactobionic acid on the survival and growth of lactobacilli probiotics. J Funct Foods. 2014; 10: 75–84.

72. Shpak M., Ryabtseva S. Lactulose effect on viability of starter cultures. JHED (Journal of Hygienic Engineering and Design). 2019; 27: 162–7.

73. Akhmedova V.R., Ryabtseva S.A., Shpak M.A. Scientific substantiation of a method for producing fermented milk ice cream with prebiotic components. Tekhnika i tekhnologiya pischevykh proizvodstv [Technique and Technology of Food Production]. 2015; (4): 5–11. (in Russian)

74. Kontareva V.Yu., Kryuchkova V.V. Sour milk biological products with bifidogenic properties: production technology and prevention of dysbiosis in the experiment: Monograph. pos. Persianovskiy: Izdatel’stvo DGAU, 2011: 104 р. (in Russian)

75. Kontareva V.Yu., Kryuchkova V.V. Study of the effect of enriched kefir products on the development of enterobacteria. Tekhnika i tekhnologiya pischevykh proizvodstv [Technique and Technology of Food Production]. 2017; 4 (47): 54–9. (in Russian)

76. WHO Model List of Essential Medicines. 21th List [Electronic resource]. 2019. URL: https://apps.who.int/iris/bitstream/handle/10665/273826/EML-20-eng.pdf. (date of access October 22, 19)

77. Lactulose [Electronic resource]. 2019. URL: https://www.ema.europa.eu/en/documents/psusa/lactulose-list-nationally-authorised-medicinal-products-psusa/00001821/201605_en.pdf. (date of access October 22, 19)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

SCImago Journal & Country Rank
Scopus CiteScore
CHIEF EDITOR
CHIEF EDITOR
Viktor A. Tutelyan
Full Member of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor, Scientific Director of the Federal Research Centre of Nutrition, Biotechnology and Food Safety (Moscow, Russia)

Journals of «GEOTAR-Media»